We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions...
Cash of €13.0m (million) as of December 31, 2023 (€17.4m as of December 31, 2022), including: The signing of an exclusivity agreement with Sanofi on M1Pram and payment of €10m The July 2023 €10m...
Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers...
Une levée de fonds pour un montant de 2 millions d’euros au bénéfice de : Gérard Soula, Président du Conseil d’Administration, Olivier Soula, Directeur Général, co-fondateurs, ainsi qu’un membre...
Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers...
Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | -8.93 | -75.8064516129 | 11.78 | 11.95 | 2.5 | 34972 | 6.46467674 | CS |
26 | -8.68 | -75.2818733738 | 11.53 | 11.96 | 2.5 | 15335 | 7.32479975 | CS |
52 | -7.99 | -73.7084870849 | 10.84 | 11.96 | 2.5 | 9613 | 8.61100801 | CS |
156 | -7.19 | -71.6135458167 | 10.04 | 11.96 | 2.5 | 12905 | 9.87923146 | CS |
260 | -7.12 | -71.4142427282 | 9.97 | 11.96 | 2.5 | 19942 | 9.98772927 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions